Copeptin as an Early Adjunct to High-Sensitivity Cardiac Troponin I in Initially Troponin-Negative Acute Myocardial Infarction: A Prospective Case–Control Study
Journal of Cardiovascular Development and Disease · 2026-11-07 · 13 (11) · 574
DOI: 10.3390/jcdd13110574 ↗Abstract
Early diagnosis of acute myocardial infarction (AMI) remains challenging in patients with initially non-elevated high-sensitivity cardiac troponin I (hs-cTnI). We assessed the diagnostic contribution of copeptin, with endothelin-1 and chemerin as exploratory comparators. This prospective, single-center case–control study included 160 adults with suspected acute coronary syndrome: 40 controls, 40 with unstable angina, 40 with non-ST-elevation myocardial infarction (NSTEMI), and 40 with ST-elevation myocardial infarction (STEMI). Samples were obtained at presentation, and diagnoses were adjudicated blinded to investigational biomarkers. Twelve of the 80 AMI cases had initially non-elevated hs-cTnI (7 STEMI; 5 NSTEMI). Copeptin was positive in 8/12 and the three-marker panel in 9/12. Among the five initially troponin-negative NSTEMI cases, all positive on repeat hs-cTnI testing, copeptin was positive in 4/5 (80.0%; 95% confidence interval, 28.4–99.5%). The hs-cTnI OR copeptin strategy increased sensitivity from 85.0% to 95.0%, while specificity among controls decreased from 95.0% to 62.5%. Adding the biomarkers to a clinical model containing hs-cTnI changed the apparent area under the curve from 0.961 to 0.965, without significantly improving model fit (likelihood-ratio p = 0.718). These findings may support evaluating adjunctive copeptin within contemporary accelerated troponin pathways.
EUVIMED